BAX and cancer: In agreement with previous studies reporting the Bax/Bcl-2 modulation and apoptosis-inducing efficacy of ITCs in various human cancer cells [22, 30], we found dose-dependent upregulation of Bax and a downregulation of Bcl-2 in SH-SY5Y cells treated with MAC.